Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Myeloma Therapies Create an ‘Optimistic Picture’ for Patients’ Futures

April 6th 2021

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

What It’s Like to Be a Myeloma Millennial, Or, ‘Myelennial’

April 5th 2021

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

Treatments for Multiple Myeloma Are Transforming Lives

April 1st 2021

The biggest fear for many patients, according to an expert from The University of Texas MD Anderson Cancer Center, is when they hear that myeloma, for most patients, is not curable. However, she notes that every few years patient survival is increasing.

FDA Approves Addition of Sarclisa to Standard of Care for Relapsed/Refractory Myeloma

March 31st 2021

“This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa to become a standard of care in relapsed or refractory multiple myeloma,” said Dr. Thomas G. Martin.

‘Knowledge Is Power’ When Learning About Treatments for Late Relapsed/Refractory Multiple Myeloma

March 31st 2021

An expert discusses therapies that are changing the treatment landscape and the research to make this disease more livable.

Many Factors Influence Which Cell-Based Treatment Options are Best for Patients with Multiple Myeloma, Expert Says

March 30th 2021

Efficacy is one of the most important drivers in determining which cell-based therapy a patient with multiple myeloma receives, according to an expert. However, she says, other factors, such as how aggressive the disease is, may play a major role.

FDA Approves First CAR-T Cell Therapy for Multiple Myeloma

March 28th 2021

Abecma is the first cell-based gene therapy approved for the treatment of patients with relapsed and refractory multiple myeloma who did not respond to at least four treatments, or whose disease returned after those four lines of therapy.

Spotlighting New and Emerging Therapies in Myeloma

March 24th 2021

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to an expert.

Multiple Myeloma 101: An Incurable But ‘Very Treatable’ Disease

March 22nd 2021

Although a multiple myeloma diagnosis can be overwhelming for patients, an expert from the Massachusetts General Hospital Cancer Center notes how the disease is very treatable, and that patients can go on to lead full lives.

The Basics of Multiple Myeloma

March 18th 2021

In this episode of the “CURE® Talks Cancer” podcast, we’re honoring Multiple Myeloma Awareness Month by speaking with Dr. Andrew Yee, about the signs and symptoms of this rare form of cancer, what the current treatment paradigm looks like and what advice he has for newly diagnosed patients.

Assessing Unique Patient Characteristics Critical in Deciding Therapy Options for Early Relapse Myeloma

March 18th 2021

An expert discusses the treatment options that patients with early relapse myeloma have to treat their recurrent disease, which often follows a cyclical pattern.

Educated Patient® Multiple Myeloma Summit: March 13, 2021

March 13th 2021

View the full CURE Educated Patient Multiple Myeloma Summit on demand.

FDA Approves Pepaxto Combination for Relapsed/Refractory Multiple Myeloma

February 27th 2021

The agency granted accelerated approval to Pepaxto in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma, who received at least four prior lines of therapy.

Novel CAR-T Cell Therapy Produces Sustainable Response in Patients with Relapsed Multiple Myeloma

February 26th 2021

Results from the phase 2 KarMMa trial showed that 73% of patients had a response to the CAR-T cell therapy, including 33% who experienced a complete response or better.

7 Recent Cancer Drug Approvals Patients May Have Missed

January 18th 2021

The Food and Drug Administration has had a busy winter so far, approving several new agents to treat a variety of cancers. Here are seven recent approvals that patients with cancer may have missed.

Triple Therapy with Darzalex Improves Pain, Quality of Life in Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation

January 14th 2021

Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response.

Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma

January 13th 2021

Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.

A Granddaughter's Questions About Cancer

January 7th 2021

A caregiver discusses with her granddaughter the cancer diagnosis and treatment of a loved one.

FDA Lifts Hold on Trial Assessing CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma

December 30th 2020

The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.

Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine

December 29th 2020

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

The Top 10 'CURE Talks Cancer' Podcasts of 2020

December 27th 2020

Here are the top 10 episodes of the “CURE Talks Cancer” podcast from 2020.

Triple Therapy with Xpovio, Velcade and Dexamethasone Improved Progression-Free Survival in Multiple Myeloma

December 21st 2020

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma

December 18th 2020

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.

Accurate Diagnosis, Staging Improves Myeloma Outcomes

December 16th 2020

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

A Beginner’s Guide to Understanding Myeloma

December 16th 2020

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.

Understanding New Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

December 15th 2020

The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.

Venclexta With Velcade and Dexamethasone May Improve Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

December 4th 2020

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma

December 4th 2020

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

The Latest News and Updates in Myeloma

October 27th 2020

A roundup of the latest news and updates for patients with myeloma from CURE®.

Adding Darzalex to Standard Treatment for High-Risk Multiple Myeloma May Delay Disease Progression

October 27th 2020

A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).

NEXT PAGE
PREVIOUS PAGE